SEC Tracker
Get the app

Hims & Hers Health HIMS

Hims & Hers Health Q1 FY26: revenue $608.1M, up 4%; diluted EPS −$0.40

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Hims & Hers Health reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$608.1M+4% from $586.0M in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$92.1M−286% from $49.5M in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.40−300% from $0.20 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$222.3M−19% from $273.7M in Q1 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$89.4M−18% from $109.1M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Hims & Hers Health files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8011 and related industry codes: the same peer list as the financial tables.

  1. Teladoc Health TDOC public float $1.5B, Jun 30, 2025
  2. LifeMD LFMD public float $512M, Jun 30, 2025
  3. Starling Oncology TOI public float $137M, Jun 30, 2025
  4. Airsculpt Technologies AIRS public float $80M, Jun 30, 2025
  5. SBC Medical Group Holdings SBC public float $48M, Jun 30, 2025